

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

Date: (Filing No. H- )

**VETERANS AND LEGAL AFFAIRS**

Reproduced and distributed under the direction of the Clerk of the House.

**STATE OF MAINE  
HOUSE OF REPRESENTATIVES  
132ND LEGISLATURE  
SECOND REGULAR SESSION**

COMMITTEE AMENDMENT “ ” to H.P. 1231, L.D. 1847, “An Act to Institute Testing and Tracking of Medical Use Cannabis and Cannabis Products Similar to Adult Use Cannabis and Cannabis Products, Dedicate a Portion of the Adult Use Cannabis Sales and Excise Tax to Medical Use Cannabis Programs and Create a Study Group”

Amend the bill by striking out the title and substituting the following:

**'An Act to Institute Testing and Tracking of Medical Use Cannabis Similar to Adult Use Cannabis and Cannabis Products, to Amend the Excise Tax Provisions for Adult Use Cannabis for Cannabis Pre-rolls and to Make Other Changes to the Medical Use and Adult Use Cannabis Programs'**

Amend the bill by striking out everything after the enacting clause and inserting the following:

**'PART A**

**Sec. A-1. 22 MRSA §2421-A, sub-§1-A** is enacted to read:

**1-A. Batch.** "Batch" means a specific quantity of cannabis flower, cannabis trim, cannabis concentrate or cannabis products harvested or manufactured at the same time under the same conditions using the same process or procedure.

**Sec. A-2. 22 MRSA §2421-A, sub-§3-A** is enacted to read:

**3-A. Cannabis flower.** "Cannabis flower" means the pistillate reproductive organs of a mature cannabis plant, whether processed or unprocessed, including the flowers and buds of the plant. "Cannabis flower" does not include cannabis trim or whole mature cannabis plants or the flower of hemp as defined in Title 7, section 2231, subsection 1-A, paragraph D.

**Sec. A-3. 22 MRSA §2421-A, sub-§6-A** is enacted to read:

**6-A. Cannabis pre-roll.** "Cannabis pre-roll" means cannabis flower, cannabis trim or a combination of cannabis flower and cannabis trim that is rolled in rolling papers.

**COMMITTEE AMENDMENT**

1 cigarette papers or wraps, with or without a cardboard filter, and intended for smoking. A  
2 cannabis pre-roll may be infused with cannabis concentrate.

3 **Sec. A-4. 22 MRSA §2421-A, sub-§8**, as enacted by PL 2023, c. 679, Pt. A, §3, is  
4 repealed and the following enacted in its place:

5 **8. Cannabis testing facility.** "Cannabis testing facility" means a facility registered in  
6 accordance with section 2425-A or a facility licensed under Title 28-B, chapter 1 to operate  
7 a testing facility.

8 **Sec. A-5. 22 MRSA §2421-A, sub-§9-A** is enacted to read:

9 **9-A. Cannabis trim.** "Cannabis trim" means any part of a cannabis plant, whether  
10 processed or unprocessed, that is not cannabis flower or a cannabis seed, except that  
11 "cannabis trim" does not include the stalks or roots of the cannabis plant. "Cannabis trim"  
12 does not include any part of a hemp plant as defined in Title 7, section 2231, subsection  
13 1-A, paragraph D.

14 **Sec. A-6. 22 MRSA §2421-A, sub-§27-A** is enacted to read:

15 **27-A. Matrix.** "Matrix" means, as applicable to the testing of harvested cannabis, the  
16 form in which harvested cannabis exists at the time it is subject to mandatory testing in  
17 accordance with this chapter. "Matrix" includes the following categories of harvested  
18 cannabis:

19 A. Cannabis flower and cannabis trim, including cannabis pre-rolls;

20 B. Cannabis concentrate, including concentrates extracted using solvents, as well as  
21 solventless extraction methods; and

22 C. Cannabis product.

23 **Sec. A-7. 22 MRSA §2421-A, sub-§45-A** is enacted to read:

24 **45-A. Remediation.** "Remediation" means the process by which a registrant mitigates  
25 or otherwise removes a contaminant from a batch of harvested cannabis that failed  
26 mandatory testing due to the presence of that contaminant. "Remediation" includes without  
27 limitation the application of heat, radiation or ozone; solvent extraction; or further drying  
28 and curing. "Remediation" does not include the dilution of contaminants through the  
29 addition of uncontaminated material to batches of harvested cannabis that are  
30 contaminated.

31 **Sec. A-8. 22 MRSA §2421-A, sub-§51-A** is enacted to read:

32 **51-A. Testing or test.** "Testing" or "test" means the analysis of harvested cannabis or  
33 other substances for contaminants, safety or potency. "Testing" or "test" includes the  
34 collection of samples of harvested cannabis for testing purposes but does not include  
35 cultivation or manufacturing.

36 **Sec. A-9. 22 MRSA §2421-A, sub-§51-B** is enacted to read:

37 **51-B. THC.** "THC" means tetrahydrocannabinol.

38 **Sec. A-10. 22 MRSA §2423-A, sub-§2, ¶M**, as repealed and replaced by PL 2019,  
39 c. 331, §11 and amended by PL 2021, c. 669, §5, is repealed.

1           **Sec. A-11. 22 MRSA §2423-A, sub-§10**, as amended by PL 2025, c. 390, Pt. A,  
2 §38 and c. 611, §3, is repealed.

3           **Sec. A-12. 22 MRSA §2423-A, sub-§12**, as repealed and replaced by PL 2019, c.  
4 331, §15 and amended by PL 2021, c. 669, §5, is repealed.

5           **Sec. A-13. 22 MRSA §2423-F, sub-§4, ¶D**, as repealed and replaced by PL 2019,  
6 c. 331, §17 and amended by PL 2021, c. 669, §5, is repealed.

7           **Sec. A-14. 22 MRSA §2423-F, sub-§5, ¶D**, as repealed and replaced by PL 2019,  
8 c. 331, §17 and amended by PL 2021, c. 669, §5, is repealed.

9           **Sec. A-15. 22 MRSA §2423-G** is enacted to read:

10           **§2423-G. Testing program established**

11           The office shall establish a testing program for harvested cannabis.

12           **1. Testing required.** Except as otherwise provided in this chapter, the testing program  
13 must require a dispensary, a caregiver or an assistant of a caregiver, prior to selling,  
14 distributing or transferring harvested cannabis to a qualifying patient or to an individual on  
15 behalf of a qualifying patient, to submit the harvested cannabis to a cannabis testing facility  
16 for testing to ensure that the harvested cannabis does not exceed the maximum level of  
17 allowable contamination for any contaminant that is injurious to health and for which  
18 testing is required and to ensure accurate labeling.

19           **2. Rules.** The office shall adopt rules establishing a testing program pursuant to this  
20 section, including, but not limited to:

21           A. Rules identifying the types of contaminants that are injurious to health for which  
22 harvested cannabis must be tested under this chapter and rules regarding the maximum  
23 level of allowable contamination for each identified contaminant;

24           B. Rules establishing testing and maximum level parameters for speciation testing of  
25 harmful yeasts and molds, including the range for allowing speciation tests for cannabis  
26 flower and cannabis trim testing, which must be set based on evidence-based practices;  
27 and

28           C. Rules establishing testing protocols that ensure consistent and accurate reporting of  
29 potency.

30           Rules adopted pursuant to this subsection are routine technical rules as defined in Title 5,  
31 chapter 375, subchapter 2-A.

32           **Sec. A-16. 22 MRSA §2423-H** is enacted to read:

33           **§2423-H. Cannabis testing facilities; requirements**

34           **1. Facility requirements.** The following requirements are applicable to the operation  
35 of a cannabis testing facility registered in accordance with this chapter regarding mandatory  
36 testing and other testing of harvested cannabis.

37           A. A testing facility that is licensed pursuant to Title 28-B, chapter 1 to test cannabis  
38 and cannabis products for harmful contaminants and cannabinoid profiles may be  
39 issued a registration certificate to operate a cannabis testing facility under this chapter,  
40 as long as the licensed testing facility is in good standing with the office and the request  
41 for a registration certificate is submitted on forms provided by the office. There is no

1 fee for a registration certificate issued to a testing facility licensed under Title 28-B,  
2 chapter 1. All employees of the cannabis testing facility that conduct mandatory and  
3 other testing on harvested cannabis shall obtain from the office a registry identification  
4 card in accordance with section 2425-A.

5 B. A person that is not licensed under Title 28-B, chapter 1 to operate a testing facility  
6 may apply for a registration certificate to operate a cannabis testing facility under this  
7 chapter in accordance with the requirements of section 2425-A. The office may not  
8 issue a registration certificate to a person pursuant to this paragraph and section 2425-A  
9 unless the applicant also demonstrates that:

10 (1) The applicant has obtained accreditation pursuant to standard ISO/IEC 17025  
11 of the International Organization for Standardization by a 3rd-party accrediting  
12 body for all fields of mandatory testing, in all matrices, required under this chapter;

13 (2) The applicant has obtained certification by the Maine Center for Disease  
14 Control and Prevention in accordance with section 569 for all fields of mandatory  
15 testing, in all matrices, required under this chapter;

16 (3) The applicant and, if the applicant is a business entity, anyone with a financial  
17 or other interest in the applicant is not a caregiver, a registered caregiver or an  
18 officer or director of a registered dispensary or manufacturing facility; and

19 (4) The applicant has obtained local authorization in accordance with section  
20 2429-D from the municipality where the cannabis testing facility will be located.

21 C. For the purposes of administering tests pursuant to this chapter, a registered cannabis  
22 testing facility is authorized to:

23 (1) Accept and possess samples of harvested cannabis for mandatory testing from  
24 registrants;

25 (2) Accept and possess samples of harvested cannabis for other testing from  
26 registrants, qualifying patients and members of the public;

27 (3) Test samples of harvested cannabis for mandatory and other testing and report  
28 the results of such testing to the registrant, qualifying patient or member of the  
29 public that submitted the samples for testing;

30 (4) Report the results of any mandatory and other testing conducted pursuant to  
31 this chapter to the office;

32 (5) Test samples of harvested cannabis that are submitted for retesting after a failed  
33 mandatory test and report the results of retesting to the registrant, qualifying patient  
34 or member of the public that submitted the samples for retesting and to the office;  
35 and

36 (6) Hire any number of cardholders necessary to conduct analyses in accordance  
37 with this chapter.

38 2. Rules. The office may adopt rules regarding the registration, certification,  
39 accreditation and operation of cannabis testing facilities authorized under this chapter,  
40 including, but not limited to, rules establishing acceptable testing practices for cannabis  
41 testing facilities, including, but not limited to, provisions relating to testing practices,  
42 methods and standards; remediation and retesting procedures; quality control analysis;

1 equipment certification and calibration; chemical identification; cannabis testing facility  
2 record-keeping, documentation and business practices; disposal of used, unused and waste  
3 harvested cannabis; and reporting of test results. The office shall, to the extent practicable,  
4 establish pass and fail requirements for cannabis testing in accordance with applicable  
5 national and international quality standards established for botanical ingredients by the  
6 American Herbal Pharmacopoeia, the United States Pharmacopeia, the European  
7 Pharmacopoeia and the British Pharmacopoeia or successor organizations. Rules adopted  
8 pursuant to this subsection are routine technical rules as defined in Title 5, chapter 375,  
9 subchapter 2-A. The office may, alternatively, require cannabis testing facilities registered  
10 pursuant to this chapter to comply with any rules and standards established for testing  
11 facilities licensed under Title 28-B, chapter 1.

12 **Sec. A-17. 22 MRSA §2425-A, first ¶**, as enacted by PL 2017, c. 452, §12 and  
13 amended by PL 2021, c. 669, §5, is further amended to read:

14 This section governs registry identification cards and registration certificates, except  
15 that registration of manufacturing facilities and persons authorized to engage in cannabis  
16 extraction is governed by section 2423-F and registration of cannabis testing facilities is  
17 governed by section ~~2423-A, subsection 10~~ 2423-H.

18 **Sec. A-18. 22 MRSA §2425-A, sub-§2**, as enacted by PL 2017, c. 452, §12, is  
19 amended to read:

20 **2. Required registration.** A caregiver, other than a caregiver operating under section  
21 2423-A, subsection 3, paragraph C, and an officer or director or assistant of a ~~dispensary~~  
22 ~~or a caregiver registrant~~, other than a caregiver operating under section 2423-A, subsection  
23 3, paragraph C, shall obtain a registry identification card in accordance with subsections 3,  
24 4 and 5. A long-term care facility designated by a qualifying patient pursuant to section  
25 2423-A, subsection 1, paragraph F-1, subparagraph (2) and a dispensary or a cannabis  
26 testing facility shall obtain a registration certificate in accordance with subsections 6, 7 and  
27 8.

28 **Sec. A-19. 22 MRSA §2425-A, sub-§6**, as amended by PL 2025, c. 611, §7, is  
29 further amended to read:

30 **6. Application for registration certificate; qualifications.** The ~~department office~~  
31 shall register and issue a registration certificate to an applicant who submits a complete  
32 application that meets the requirements of this subsection.

33 The ~~department office~~ shall conduct a criminal history record check pursuant to section  
34 2425-B for each officer or director of the applicant for a registration certificate. The  
35 ~~department office~~ may not issue a registration certificate to an applicant if any officer or  
36 director of the applicant has been convicted of a disqualifying drug offense.

37 An application must include, as applicable:

- 38 A. The annual fee required pursuant to subsection 10;
- 39 B. Evidence of the applicant's registration with the Secretary of State and evidence  
40 that the applicant is in good standing with the Secretary of State; ~~and~~
- 41 C. The name, address and date of birth of each officer or director of the applicant; ~~;~~
- 42 D. For applicants for a dispensary registration certificate, plans for compliance with  
43 the requirements of section 2428; and

1 E. For applicants for a cannabis testing facility registration certificate, demonstration  
2 that the applicant is in compliance with the requirements of section 2423-H.

3 **Sec. A-20. 22 MRSA §2428, sub-§1-A, ¶G,** as repealed and replaced by PL 2019,  
4 c. 331, §25 and amended by PL 2021, c. 669, §5, is repealed.

5 **Sec. A-21. 22 MRSA §2429-A, sub-§1, ¶C,** as enacted by PL 2017, c. 452, §18  
6 and amended by PL 2021, c. 669, §5, is further amended to read:

7 C. Packaged in a container with an integral measurement component and child-  
8 resistant cap if the cannabis product is a multiserving liquid; ~~and~~

9 **Sec. A-22. 22 MRSA §2429-A, sub-§1, ¶C-1** is enacted to read:

10 C-1. Packaged in a manner that does not introduce harmful contaminants to the  
11 harvested cannabis after it has passed mandatory testing required under this chapter;  
12 and

13 **Sec. A-23. 22 MRSA §2429-A, sub-§3,** as enacted by PL 2017, c. 452, §18 and  
14 amended by PL 2021, c. 669, §5, is further amended to read:

15 **3. Labels.** ~~If a~~ A registered caregiver, registered dispensary or manufacturing facility  
16 affixes shall affix a label on the packaging of any harvested cannabis provided to a  
17 qualifying patient, and that label ~~includes~~ must include information about contaminants,  
18 the cannabinoid profile ~~or~~ and potency of the harvested cannabis, ~~the label and~~ and must be  
19 verified by a cannabis testing facility. ~~This subsection does not apply if there is no cannabis~~  
20 ~~testing facility operating in accordance with section 2423-A, subsection 10.~~

21 **Sec. A-24. 22 MRSA §2429-C, sub-§1-A** is enacted to read:

22 **1-A. Cannabinoid potency.** May have the amount or potency of cannabinoids  
23 calculated using an allowable variance rate of 10%. In the calculation of the amount or  
24 potency of cannabinoids allowed under this subsection, the allowable variance rate may be  
25 in addition to the allowable variance rate applicable to a cannabis testing facility pursuant  
26 to section 2430-O, subsection 7;

27 **Sec. A-25. 22 MRSA §2430, sub-§3-A, ¶C,** as enacted by PL 2025, c. 368, §3, is  
28 amended to read:

29 C. Grants to organizations in the State conducting outreach and providing support  
30 services to active duty military members and their families who are transitioning to  
31 civilian life. Notwithstanding any provision of law to the contrary, on or before  
32 September 30, 2025, and by every September 30th thereafter, the State Controller shall  
33 transfer \$200,000 from the fund to the Active Duty Military Transition to Civilian Life  
34 Fund established within the Department of Economic and Community Development  
35 under Title 5, section 13056-K to administer grants issued pursuant to this paragraph;  
36 ~~and~~

37 **Sec. A-26. 22 MRSA §2430, sub-§3-A, ¶D,** as enacted by PL 2025, c. 368, §3, is  
38 amended to read:

39 D. Grants to organizations in the State providing housing and support services for  
40 unhouseed veterans and their children and for survivors of military sexual trauma.  
41 Notwithstanding any provision of law to the contrary, on or before September 30, 2025,  
42 and by every September 30th thereafter, the State Controller shall transfer \$285,000

1 from the fund to the Survivors of Military Sexual Trauma Fund under section 3971 to  
2 administer grants issued pursuant to this paragraph; and

3 **Sec. A-27. 22 MRSA §2430, sub-§3-A, ¶E** is enacted to read:

4 E. Reimbursements to qualifying registrants for a portion of the costs of batch testing  
5 required under section 2430-O. For the purposes of this paragraph, "qualifying  
6 registrant" means a registrant subject to mandatory testing under section 2430-O whose  
7 gross annual revenue generated from authorized conduct under this chapter is less than  
8 \$125,000 and whose annual total testing costs for testing required under section  
9 2430-O is greater than 10% of the registrant's gross annual revenue. Reimbursements  
10 under this paragraph must be \$100 per batch tested pursuant to section 2430-O for the  
11 year in which the registrant qualifies. The office may adopt rules to implement and  
12 administer reimbursement of qualifying registrants under this paragraph. Rules adopted  
13 pursuant to this paragraph are routine technical rules as defined in Title 5, chapter 375,  
14 subchapter 2-A.

15 **Sec. A-28. 22 MRSA §2430-J**, as enacted by PL 2023, c. 365, §21, is amended to  
16 read:

17 **§2430-J. Reporting; record-keeping; labels Records; inventory tracking information**

18 The ~~department office~~ shall ~~develop~~, implement and ~~maintain~~ administer a statewide  
19 electronic portal inventory tracking system through which registered caregivers, registered  
20 dispensaries, cannabis testing facilities and manufacturing facilities ~~may~~ shall submit to the  
21 ~~department office~~ the electronic records required pursuant to this chapter. Registrants of  
22 the inventory tracking system shall pay all costs and fees associated with the use of the  
23 inventory tracking system and all other costs associated with the keeping of records  
24 required in this section. The department office may not require records submitted through  
25 the portal maintained in the inventory tracking system to contain information identifying  
26 qualifying patients or their medical providers.

27 **1. Required records.** A registered caregiver, a registered dispensary, a cannabis  
28 testing facility and a manufacturing facility shall:

29 A. Keep a record of all ~~transfers of~~ cannabis plants and harvested cannabis from  
30 immature cannabis plant to the point of sale or transfer to a qualifying patient, return,  
31 disposal or destruction; and

32 B. Keep the ~~books and~~ records for a period of 4 6 years; ~~and.~~

33 C. ~~Make the books and records maintained under this subsection available for~~  
34 ~~inspection by the department upon the department's request.~~

35 **2. Required label.** ~~A registered caregiver, registered dispensary, cannabis testing~~  
36 ~~facility and manufacturing facility shall accompany all cannabis plants and harvested~~  
37 ~~cannabis being transported pursuant to this chapter with a label that identifies:~~

38 A. ~~The person transferring the cannabis plants or harvested cannabis, including the~~  
39 ~~person's registry identification number;~~

40 B. ~~The person receiving the cannabis plants or harvested cannabis, including the~~  
41 ~~person's registry identification number or, if the person is not required to register under~~  
42 ~~this chapter, a unique identifier assigned to the person;~~

1 ~~C. A description of the cannabis plants or harvested cannabis being transferred,~~  
2 ~~including the amount and form;~~

3 ~~D. The time and date of the transfer; and~~

4 ~~E. The destination of the cannabis plants or harvested cannabis.~~

5 ~~The department may adopt rules to implement this subsection. Rules adopted pursuant to~~  
6 ~~this subsection are major substantive rules as defined in Title 5, chapter 375, subchapter~~  
7 ~~2-A.~~

8 **2-A. Required inventory tracking information.** Registrants of the inventory  
9 tracking system shall submit to the office by 11:59 p.m. every day the following  
10 information through the inventory tracking system:

11 A. A complete inventory of all cannabis plants and harvested cannabis cultivated,  
12 manufactured, stored or otherwise within the possession or control of the registrant;

13 B. A record of all transfers of cannabis plants or harvested cannabis transferred to or  
14 from the registrant that includes, at a minimum:

15 (1) The person transferring the cannabis plants or harvested cannabis, including  
16 the person's registry identification number;

17 (2) The person receiving the cannabis plants or harvested cannabis, including the  
18 person's registry identification number or, if the person is not required to register  
19 under this chapter, a unique identifier assigned to the person.

20 A registrant transferring cannabis plants or harvested cannabis to a person who is  
21 not required to register under this chapter shall maintain and produce to the office  
22 upon request a list that identifies the unique identifier and the person to whom that  
23 identifier is assigned;

24 (3) A description of the cannabis plants or harvested cannabis being transferred,  
25 including the amount and form;

26 (4) The time and date of the transfer; and

27 (5) The destination of the cannabis plants or harvested cannabis; and

28 C. A record of all mandatory test results for each batch of harvested cannabis offered  
29 to qualifying patients.

30 This subsection may not be construed to require a registrant to resubmit inventory tracking  
31 information to the office if no changes have been made to the inventory maintained by the  
32 registrant.

33 The office may adopt rules to implement this section, including, but not limited to,  
34 rules regarding the process and content of records to be submitted and the frequency with  
35 which records must be submitted, as well as rules regarding enforcement of the inventory  
36 tracking requirements of this chapter. Rules adopted pursuant to this paragraph are routine  
37 technical rules as defined in Title 5, chapter 375, subchapter 2-A.

38 **Sec. A-29. 22 MRSA §2430-O** is enacted to read:

39 **§2430-O. Mandatory testing**

1           A registered caregiver, dispensary or manufacturing facility may not sell, distribute or  
2 transfer harvested cannabis to a qualifying patient or to an individual on behalf of a  
3 qualifying patient unless the harvested cannabis has been tested pursuant to this chapter  
4 and that testing demonstrates that the harvested cannabis does not exceed the maximum  
5 level of allowable contamination for any contaminant for which testing is required, as  
6 applicable, based upon the matrix in which the harvested cannabis is intended to be used  
7 by a qualifying patient. The office may require testing for some analytes in some matrices  
8 before the harvested cannabis is further processed, manufactured or combined to ensure  
9 that contaminants that are injurious to health do not contaminate other batches of harvested  
10 cannabis. All cannabis concentrates used to manufacture cannabis products in accordance  
11 with this chapter must be tested in accordance with subsection 3 or 4 prior to being used to  
12 manufacture a cannabis product or a cannabis pre-roll infused with cannabis concentrate.

13           The office may temporarily waive mandatory testing requirements under this section  
14 for any contaminant or factor for which the office has determined that there exists no  
15 cannabis testing facility in the State capable of and authorized to perform such testing.

16           **1. Scope of mandatory testing generally.** Mandatory testing of harvested cannabis  
17 under this section must include, but is not limited to, testing for:

18           A. Residual solvents, poisons and toxins;

19           B. Metals;

20           C. Dangerous molds and mildew, including, but not limited to, Aspergillus spp. and  
21 mycotoxins, as applicable;

22           D. Harmful microbes, including, but not limited to, Escherichia coli and Salmonella;

23           E. Pesticides, fungicides and insecticides;

24           F. Water activity, for harvested cannabis except cannabis concentrate; and

25           G. THC potency, homogeneity and cannabinoid profiles.

26           **2. Scope of mandatory testing for cannabis flower and cannabis trim.** Cannabis  
27 flower and cannabis trim, including cannabis pre-rolls and cannabis flower or cannabis trim  
28 that has been mixed with cannabis concentrate, must be tested for:

29           A. Metals;

30           B. Dangerous molds and mildew, including, but not limited to, Aspergillus spp. and  
31 mycotoxins, as applicable. Testing for mycotoxins is mandatory if the batch fails  
32 mandatory testing for dangerous molds and mildew and is subsequently retested;

33           C. Harmful microbes;

34           D. Pesticides, fungicides and insecticides;

35           E. Water activity; and

36           F. THC potency and cannabinoid profiles.

37           **3. Scope of mandatory testing for cannabis concentrate extracted using solvents**  
38 **other than water.** Cannabis concentrate that has been extracted using solvents other than  
39 water must be tested for:

40           A. Residual solvents, poisons and toxins;

- 1           B. Metals;
- 2           C. Pesticides, fungicides and insecticides;
- 3           D. Mycotoxins; and
- 4           E. THC potency, homogeneity and cannabinoid profiles.

5           **4. Scope of mandatory testing for cannabis concentrate extracted without use of**  
6 **solvents other than water.** Cannabis concentrate that has been extracted without the use  
7 of solvents other than water must be tested for:

- 8           A. Metals;
- 9           B. Dangerous molds and mildew, including, but not limited to, Aspergillus spp. and  
10 mycotoxins, as applicable. Testing for mycotoxins is mandatory if the batch fails  
11 mandatory testing for dangerous molds and mildew and is subsequently retested;
- 12           C. Harmful microbes;
- 13           D. Pesticides, fungicides and insecticides; and
- 14           E. THC potency, homogeneity and cannabinoid profiles.

15           **5. Scope of mandatory testing for cannabis products.** Cannabis products, including  
16 edible cannabis products, must be tested for:

- 17           A. Dangerous molds and mildew, including, but not limited to, Aspergillus spp. and  
18 mycotoxins, as applicable. Testing for mycotoxins is mandatory if the batch fails  
19 mandatory testing for dangerous molds and mildew and is subsequently retested;
- 20           B. Harmful microbes;
- 21           C. Water activity, except that edible cannabis products that are preserved by  
22 refrigeration are not required to be tested for water activity; and
- 23           D. THC potency, homogeneity and cannabinoid profiles.

24           **6. Record keeping.** A registrant, not exempt under subsection 8, shall maintain a  
25 record of all mandatory testing that includes a description of the harvested cannabis  
26 provided to the cannabis testing facility, the identity of the cannabis testing facility and the  
27 results of the mandatory test. The results of all mandatory tests conducted by a cannabis  
28 testing facility must be recorded in accordance with the record-keeping and inventory  
29 tracking requirements of section 2430-J.

30           **7. Sample collection, testing processes, protocols and standards.** The office may  
31 establish by rule processes, protocols and standards for the collection of samples for  
32 mandatory testing and for the mandatory and other testing of harvested cannabis that  
33 conform with the best practices generally used to sample the applicable matrices and test  
34 for the presence or absence of the contaminants identified in this section based upon the  
35 matrix of the harvested cannabis tested. The rules may include an allowable variance rate  
36 for determining the amount or potency of THC or other cannabinoids in edible cannabis  
37 products. The office shall, to the extent practicable, establish pass and fail requirements for  
38 cannabis testing in accordance with applicable national and international quality standards  
39 established for botanical ingredients by the American Herbal Pharmacopoeia, the United  
40 States Pharmacopoeia, the European Pharmacopoeia and the British Pharmacopoeia or  
41 successor organizations. Rules adopted pursuant to this subsection are routine technical

1 rules as defined in Title 5, chapter 375, subchapter 2-A. The office may, alternatively,  
2 require registrants to comply with any rules and standards established for testing cannabis  
3 under Title 28-B, chapter 1.

4 **8. Exemption from mandatory testing.** Harvested cannabis cultivated by a registered  
5 caregiver who meets the following criteria is exempt from the mandatory testing  
6 requirements in this section:

7 A. The registered caregiver's cultivation area is located at the registered caregiver's  
8 primary residence;

9 B. The registered caregiver does not have a 2nd cultivation area located on property  
10 that is not the registered caregiver's primary residence;

11 C. The registered caregiver's cultivation area does not exceed 500 square feet of mature  
12 plant canopy or 30 mature plants;

13 D. There are no other registered caregivers with a cultivation area on the property  
14 where the registered caregiver's cultivation area is located with the exception of one  
15 family member who shares a primary residence with the registered caregiver and the  
16 combined cultivation area does not exceed a total of 1,000 square feet of mature plant  
17 canopy or 60 mature plants; and

18 E. The registered caregiver, or any other family or household member who cultivates  
19 at the primary residence of the registered caregiver, does not engage in wholesale  
20 transactions.

21 The office shall adopt rules for certifying that a registered caregiver meets the criteria in  
22 this subsection. Harvested cannabis that is exempt from testing pursuant to this section  
23 must include the following warning statement: "NOT TESTED FOR RESIDUAL  
24 SOLVENTS, POISONS, TOXINS, HARMFUL CHEMICALS, DANGEROUS YEASTS,  
25 MOLDS AND MILDEWS, HARMFUL MICROBES, PESTICIDES, FUNGICIDES AND  
26 INSECTICIDES." The warning statement must appear on the front or the most  
27 prominently displayed side of any marketing layer, must appear in bold and must be no  
28 smaller than 12-point font or 1/12 inch. Rules adopted pursuant to this subsection are  
29 routine technical rules as defined in Title 5, chapter 375, subchapter 2-A.

30 **9. Maximum batch size for mandatory testing.** For the purpose of sampling and  
31 mandatory testing under this section, a batch may not exceed 44 pounds by net weight,  
32 regardless of matrix.

33 A. For cannabis flower and cannabis trim, including cannabis pre-rolls, the 44-pound  
34 limit applies to the combined net weight of cannabis flower or cannabis trim harvested  
35 or manufactured at the same time under the same conditions using the same process or  
36 procedure.

37 B. For cannabis concentrate and cannabis products, the 44-pound limit applies to the  
38 combined net weight of the finished material in that matrix that is manufactured at the  
39 same time under the same conditions using the same process or procedure.

40 The office may adopt rules for sample collection that ensure representative sampling within  
41 the 44-pound maximum batch size in accordance with subsection 7. Rules adopted pursuant  
42 to this subsection are routine technical rules as defined in Title 5, chapter 375, subchapter  
43 2-A.

1           **Sec. A-30. 22 MRSA §2430-P** is enacted to read:

2           **§2430-P. Notification requirements**

3           **1. Notification of testing results required.** If the results of a mandatory test  
4 conducted pursuant to section 2430-O indicate that the harvested cannabis exceeds the  
5 maximum level of allowable contamination for any contaminant that is injurious to health  
6 and for which testing is required, the cannabis testing facility shall immediately notify the  
7 office and the registered caregiver, dispensary or manufacturing facility that submitted the  
8 samples for mandatory testing of the failed test. If a registered caregiver, dispensary or  
9 manufacturing facility successfully undertakes remediation and retesting of harvested  
10 cannabis, the cannabis testing facility shall notify the office of the subsequent passed  
11 mandatory testing.

12           **2. Notification of testing results not required.** A cannabis testing facility is not  
13 required to notify the office of the results of any test conducted on:

14           A. Harvested cannabis at the direction of a registered caregiver, dispensary or  
15 manufacturing facility pursuant to section 2430-O that demonstrates that the harvested  
16 cannabis does not exceed the maximum level of allowable contamination for any  
17 contaminant that is injurious to health and for which testing is required;

18           B. Harvested cannabis at the direction of a registered caregiver, dispensary or  
19 manufacturing facility for research and development purposes only, as long as the  
20 registered caregiver, dispensary or manufacturing facility notifies the cannabis testing  
21 facility prior to the performance of the test that the testing is for research and  
22 development purposes only;

23           C. Harvested cannabis at the direction of a person who is not a registered caregiver,  
24 dispensary or manufacturing facility; or

25           D. A substance that is not harvested cannabis.

26           **Sec. A-31. 22 MRSA §2430-Q** is enacted to read:

27           **§2430-Q. Sample collection for testing**

28           **1. Sample collecting rules.** A registered caregiver, an assistant of a registered  
29 caregiver, a dispensary, a manufacturing facility, a sample collector licensed pursuant to  
30 Title 28-B, chapter 1 or an employee of a sample collector or cannabis testing facility may  
31 collect samples of harvested cannabis for mandatory testing. The office may adopt rules  
32 regarding the collection of samples of harvested cannabis for mandatory testing by a  
33 registered caregiver, an assistant of a registered caregiver, a dispensary, a manufacturing  
34 facility, a sample collector licensed pursuant to Title 28-B, chapter 1 or an employee of a  
35 sample collector or cannabis testing facility, which may include, but are not limited to:

36           A. Establishment of sample collecting processes, protocols and standards, which must  
37 be complied with by any person collecting samples of harvested cannabis for  
38 mandatory testing purposes;

39           B. Requirements for a registered caregiver, an assistant of a registered caregiver, a  
40 dispensary or a manufacturing facility to demonstrate that the sample collector's sample  
41 collecting practices comply with paragraph A;

1 C. Provisions authorizing the office to conduct audits of harvested cannabis that was  
2 tested using samples collected by a registered caregiver, an assistant of a registered  
3 caregiver, a dispensary or a manufacturing facility pursuant to this section, with all  
4 costs of the audits to be paid for by the registered caregiver, assistant of a registered  
5 caregiver, dispensary or manufacturing facility subject to an audit of that sample  
6 collector's sample collecting practices;

7 D. Provisions authorizing the office to take samples of harvested cannabis from a  
8 registrant, including from a retail location maintained by a registrant, for testing by a  
9 cannabis testing facility to audit or verify mandatory test results issued by the cannabis  
10 testing facility, with all costs of the testing to be paid for by the registrant;

11 E. Provisions authorizing the office to conduct interlaboratory proficiency testing to  
12 ensure cannabis testing facility compliance with testing program requirements and to  
13 ensure the quality, consistency and reliability of mandatory testing conducted by  
14 cannabis testing facilities authorized pursuant to this chapter;

15 F. Requirements for the transportation, delivery and transfer of samples of harvested  
16 cannabis collected by a registered caregiver, an assistant of a registered caregiver, a  
17 dispensary or a manufacturing facility to a cannabis testing facility, which must require  
18 the in-person transfer of the samples by the registered caregiver, the assistant of a  
19 registered caregiver, the dispensary or the manufacturing facility to a cannabis testing  
20 facility; and

21 G. A prohibition on the intentional tampering with or interference in the mandatory  
22 testing process or auditing process, including failure of any audit conducted in  
23 accordance with paragraph C, by a registered caregiver, an assistant of a registered  
24 caregiver, a dispensary or a manufacturing facility, which, notwithstanding any  
25 provision of this chapter to the contrary, may be treated by the office as constituting a  
26 violation of program requirements and as a basis for imposition of a penalty pursuant  
27 to section 2430-I, subsection 2, as applicable.

28 **2. Samples for investigation.** This section may not be construed to limit the authority  
29 of the office to take samples of harvested cannabis pursuant to an investigation by the office  
30 into the conduct of a registrant or a registrant agent.

31 **3. Rules.** Rules adopted pursuant to this section are routine technical rules as defined  
32 in Title 5, chapter 375, subchapter 2-A.

33 **Sec. A-32. 22 MRSA §2430-R** is enacted to read:

34 **§2430-R. Additional testing not required**

35 Notwithstanding section 2430-O, a registered caregiver, an assistant of a registered  
36 caregiver, a dispensary or a manufacturing facility may sell, transfer or otherwise furnish  
37 to a qualifying patient or caregiver or to another registered caregiver, assistant of a  
38 registered caregiver, dispensary or manufacturing facility harvested cannabis that the  
39 registered caregiver, assistant of a registered caregiver, dispensary or manufacturing  
40 facility has not submitted for testing in accordance with this chapter if:

41 **1. Prior testing.** The harvested cannabis has previously undergone all required testing  
42 in accordance with this chapter at the direction of another registered caregiver, assistant of  
43 a registered caregiver, dispensary or manufacturing facility and that testing demonstrated

1 that the harvested cannabis does not exceed the maximum level of allowable contamination  
2 for any contaminant that is injurious to health and for which testing is required;

3 **2. Proper documentation.** The mandatory testing process and the test results for the  
4 harvested cannabis are documented in accordance with the requirements of this chapter;

5 **3. Tracking maintained.** Tracking from immature cannabis plant to the point of sale  
6 or transfer to a qualifying patient, or another individual on behalf of a qualifying patient,  
7 has been maintained for the harvested cannabis and transfers of the harvested cannabis to  
8 another registered caregiver, assistant of a registered caregiver, dispensary or  
9 manufacturing facility or to a qualifying patient or caregiver on behalf of a qualifying  
10 patient can be readily identified; and

11 **4. No further processing, manufacturing or alteration.** Since the performance of  
12 the prior testing under subsection 1, the harvested cannabis has not undergone any further  
13 processing, manufacturing or alteration other than the packaging and labeling of the  
14 harvested cannabis in accordance with this chapter. For the purposes of this subsection,  
15 "further processing, manufacturing or alteration" does not include the use of cannabis  
16 concentrate in the creation of an edible cannabis product, except for testing under section  
17 2430-O, subsection 5, paragraph D.

18 **Sec. A-33. 22 MRSA §2430-S** is enacted to read:

19 **§2430-S. Patient education**

20 In addition to the educational materials required under section 2429-A, subsection 4,  
21 registrants shall provide educational materials to the qualifying patient at the time of sale,  
22 in printed or electronic form, about product dosing; delayed onset and duration; risks of  
23 overconsumption and impairment; considerations for individuals inexperienced with  
24 cannabis or at risk for psychiatric problems; and safe storage to prevent access by children  
25 and pets. The office shall develop and make publicly available minimum content  
26 requirements for such educational materials. In developing minimum content requirements  
27 for educational materials under this section, the office may consult with the Maine Center  
28 for Disease Control and Prevention and the Northern New England Poison Center or  
29 successor organization.

30 **PART B**

31 **Sec. B-1. 28-B MRSA §102-A, sub-§14-A** is enacted to read:

32 **14-A. Cannabis pre-roll.** "Cannabis pre-roll" means cannabis flower, cannabis trim  
33 or a combination of cannabis flower and cannabis trim that is rolled in rolling papers,  
34 cigarette papers or wraps, with or without a cardboard filter, and intended for smoking. A  
35 cannabis pre-roll may be infused with cannabis concentrate.

36 **Sec. B-2. 28-B MRSA §102-A, sub-§40-A** is enacted to read:

37 **40-A. Matrix.** "Matrix" means, as applicable to the testing of adult use cannabis or  
38 adult use cannabis products, the form in which the adult use cannabis or adult use cannabis  
39 product exists at the time it is subject to mandatory testing in accordance with this chapter.  
40 "Matrix" includes the following categories of adult use cannabis and adult use cannabis  
41 products:

42 A. Cannabis flower and cannabis trim, including cannabis pre-rolls;

1 B. Cannabis concentrate, including concentrates extracted using solvents, as well as  
2 solventless extraction methods; and

3 C. Cannabis product.

4 **Sec. B-3. 28-B MRSA §102-A, sub-§64**, as enacted by PL 2023, c. 679, Pt. B, §3,  
5 is amended to read:

6 **64. Testing facility.** "Testing facility" means a facility licensed under this chapter to  
7 develop, research and test cannabis; and cannabis products and other substances or a facility  
8 registered in accordance with Title 22, chapter 558-C.

9 **Sec. B-4. 28-B MRSA §602, first ¶**, as amended by PL 2021, c. 612, §2 and c.  
10 669, §5, is further amended to read:

11 A licensee may not sell or distribute adult use cannabis or an adult use cannabis product  
12 to a consumer under this chapter unless the cannabis or cannabis product has been tested  
13 pursuant to this subchapter and the rules adopted pursuant to this subchapter and that  
14 mandatory testing has demonstrated that the cannabis or cannabis product does not exceed  
15 the maximum level of allowable contamination for any contaminant that is injurious to  
16 health and for which testing is required. The office may require testing for some analytes  
17 in some matrices before the cannabis or cannabis product is further processed,  
18 manufactured or combined to ensure that contaminants that are injurious to health do not  
19 contaminate other batches of cannabis or cannabis product. All cannabis concentrates used  
20 to manufacture cannabis products in accordance with this chapter must be tested in  
21 accordance with subsection 1-C or 1-D prior to being used to manufacture a cannabis  
22 product or a cannabis pre-roll infused with cannabis concentrate. The office shall also adopt  
23 rules establishing testing and maximum level parameters for speciation testing, including  
24 the range for allowing speciation tests for cannabis flower and cannabis trim testing, which  
25 must be set based on evidence-based practices.

26 **Sec. B-5. 28-B MRSA §602, sub-§1**, as amended by PL 2023, c. 679, Pt. B, §§113  
27 and 114, is further amended to read:

28 **1. Scope of mandatory testing.** Mandatory testing of adult use cannabis and adult  
29 use cannabis products under this section must include, but is not limited to, testing for:

30 A. Residual solvents, poisons and toxins;

31 B. ~~Harmful chemicals~~ Metals;

32 C. Dangerous yeasts, molds and mildew ~~as specified in rules adopted by the office,~~  
33 including, but not limited to, Aspergillus spp. and mycotoxins, as applicable;

34 D. Harmful microbes, including, but not limited to, Escherichia coli and ~~salmonella~~  
35 Salmonella;

36 E. Pesticides, fungicides and insecticides; ~~and~~

37 F. THC potency, homogeneity and cannabinoid profiles ~~to ensure correct labeling;~~  
38 and

39 G. Water activity, except for cannabis concentrate.

1 The office may temporarily waive mandatory testing requirements under this section for  
2 any contaminant or factor for which the office has determined that there exists no licensed  
3 testing facility in the State capable of and certified to perform such testing.

4 **Sec. B-6. 28-B MRSA §602, sub-§1-B** is enacted to read:

5 **1-B. Scope of mandatory testing; cannabis flower and cannabis trim.** Except as  
6 provided in section 605, subsection 4, cannabis flower and cannabis trim, including  
7 cannabis pre-rolls and cannabis flower or cannabis trim that has been mixed with cannabis  
8 concentrate, must be tested for:

9 A. Metals;

10 B. Dangerous molds and mildew, including, but not limited to, Aspergillus spp. and  
11 mycotoxins, as applicable. Testing for mycotoxins is mandatory if the batch fails  
12 mandatory testing for dangerous molds and mildew and is subsequently retested;

13 C. Harmful microbes;

14 D. Pesticides, fungicides and insecticides;

15 E. Water activity; and

16 F. THC potency and cannabinoid profiles.

17 **Sec. B-7. 28-B MRSA §602, sub-§1-C** is enacted to read:

18 **1-C. Scope of mandatory testing; cannabis concentrate extracted using solvents**  
19 **other than water.** Cannabis concentrate that has been extracted using solvents other than  
20 water must be tested for:

21 A. Residual solvents, poisons and toxins;

22 B. Metals;

23 C. Pesticides, fungicides and insecticides;

24 D. Mycotoxins; and

25 E. THC potency, homogeneity and cannabinoid profiles.

26 **Sec. B-8. 28-B MRSA §602, sub-§1-D** is enacted to read:

27 **1-D. Scope of mandatory testing; cannabis concentrate extracted without use of**  
28 **solvents other than water.** Cannabis concentrate that has been extracted without the use  
29 of solvents other than water must be tested for:

30 A. Metals;

31 B. Dangerous molds and mildew, including, but not limited to, Aspergillus spp. and  
32 mycotoxins, as applicable. Testing for mycotoxins is mandatory if the batch fails  
33 mandatory testing for dangerous molds and mildew and is subsequently retested;

34 C. Harmful microbes;

35 D. Pesticides, fungicides and insecticides; and

36 E. THC potency, homogeneity and cannabinoid profiles.

37 **Sec. B-9. 28-B MRSA §602, sub-§1-E** is enacted to read:

1 **1-E. Scope of mandatory testing; cannabis products.** Cannabis products, including  
2 edible cannabis products, must be tested for:

3 A. Dangerous molds and mildew, including, but not limited to, Aspergillus spp. and  
4 mycotoxins, as applicable. Testing for mycotoxins is mandatory if the batch fails  
5 mandatory testing for dangerous molds and mildew and is subsequently retested;

6 B. Harmful microbes;

7 C. Water activity, except that edible cannabis products that are preserved by  
8 refrigeration are not required to be tested for water activity; and

9 D. THC potency, homogeneity and cannabinoid profiles.

10 **Sec. B-10. 28-B MRSA §602, sub-§1-F** is enacted to read:

11 **1-F. Maximum batch size for mandatory testing.** For the purpose of sampling and  
12 mandatory testing under this section, a batch may not exceed 44 pounds by net weight,  
13 regardless of matrix.

14 A. For cannabis flower and cannabis trim, including cannabis pre-rolls, the 44-pound  
15 limit applies to the combined net weight of cannabis flower or cannabis trim harvested  
16 or manufactured at the same time under the same conditions using the same process or  
17 procedure.

18 B. For cannabis concentrate and cannabis products, the 44-pound limit applies to the  
19 combined net weight of the finished material in that matrix that is manufactured at the  
20 same time under the same conditions using the same process or procedure.

21 The office may adopt rules for sample collection that ensure representative sampling within  
22 the 44-pound maximum batch size.

23 **Sec. B-11. 28-B MRSA §605, sub-§4**, as amended by PL 2023, c. 679, Pt. B, §120,  
24 is further amended to read:

25 **4. No subsequent further processing, manufacturing or alteration.** Since the  
26 performance of the prior testing under subsection 1, the cannabis or cannabis product has  
27 not undergone any further processing, manufacturing or alteration that would result in an  
28 increase in the concentration of any contaminants or factors identified in section 602,  
29 subsection 1 or in any rules adopted by the office pursuant to that section. For the purposes  
30 of this subsection, "further processing, manufacturing or alteration" does not include the  
31 use of cannabis concentrate in the creation of an edible cannabis product, except for testing  
32 under section 602, subsection 1-E, paragraph D.

33 **Sec. B-12. 28-B MRSA §1101, sub-§2, ¶B-1** is enacted to read:

34 B-1. Money credited to the fund may be expended by the office to fund research on  
35 the public health impacts of cannabis use, including, but not limited to, cannabis use  
36 by individuals under 21 years of age.

### 37 PART C

38 **Sec. C-1. 36 MRSA §4921, sub-§7-A** is enacted to read:

39 **7-A. Cannabis pre-roll.** "Cannabis pre-roll" has the same meaning as in Title 28-B,  
40 section 102-A, subsection 14-A.



- 1           2. It clarifies that only cannabis testing facilities may conduct testing.
- 2           3. It adds certain requirements related to testing to the provisions on packaging and  
3 labeling.
- 4           4. It establishes a program for mandatory testing of harvested cannabis.
- 5           5. It replaces previous authorization for cannabis testing facilities with a provision  
6 establishing a cannabis testing facility registration and establishes additional requirements  
7 necessary to obtain a registration certificate to operate a cannabis testing facility.
- 8           6. It includes cannabis testing facilities in the standard application process for a  
9 registration certificate.
- 10          7. It authorizes the Department of Administrative and Financial Services, Office of  
11 Cannabis Policy to use funds from the Medical Use of Cannabis Fund to provide \$100  
12 reimbursements to qualifying registrants in the medical use of cannabis program. It  
13 establishes the criteria for qualifying for reimbursements and authorizes the department to  
14 develop rules for the reimbursement program.
- 15          8. It revises reporting and record-keeping requirements to require records retention for  
16 6 years and to mandate that all registrants report all required inventory information in the  
17 statewide inventory tracking system implemented and administered by the office.
- 18          9. It requires the testing of harvested cannabis provided to a qualifying patient by a  
19 registrant.
- 20          10. It requires mandatory testing of all harvested cannabis for the presence of harmful  
21 contaminants and cannabinoid profiles.
- 22          11. It exempts cannabis flower and cannabis trim cultivated by a registered caregiver  
23 who meets certain criteria regarding cultivation area and amount cultivated and who does  
24 not engage in wholesale transactions from mandatory testing. A warning statement  
25 indicating that the cannabis flower or cannabis trim is not tested is required.
- 26          12. It specifies that the maximum size of a batch for mandatory testing is 44 pounds.
- 27          13. It requires reporting of mandatory test results of failed tests to the office and to the  
28 registrant that submitted samples to a cannabis testing facility for testing.
- 29          14. It establishes sampling requirements and permits the office to take samples for audit  
30 testing to verify mandatory test results and to ensure the quality, consistency and reliability  
31 of the testing program.
- 32          15. It identifies the circumstances in which additional mandatory testing is not required  
33 before harvested cannabis is provided to a qualifying patient.
- 34          16. It requires registrants to provide certain educational materials to qualifying patients  
35 at the time of sale.
- 36          Part B of the amendment makes the following changes to the Cannabis Legalization  
37 Act.
- 38            1. It adds definitions of "cannabis pre-roll" and "matrix."
- 39            2. It amends the definition of "testing facility" to include a registered cannabis testing  
40 facility under the Maine Medical Use of Cannabis Act.

1 3. It identifies what tests for harmful contaminants are mandatory for adult use cannabis  
2 and adult use cannabis products based upon the matrix of the cannabis or cannabis product  
3 at the time it is subject to mandatory testing.

4 4. It specifies that the maximum size of a batch for mandatory testing is 44 pounds.

5 5. It provides exemptions from final form testing for cannabis pre-rolls and edible  
6 cannabis products.

7 6. It authorizes funds from the Adult Use Cannabis Public Health and Safety and  
8 Municipal Opt-in Fund to be used for research on public health impacts of cannabis use,  
9 including use by individuals who have not attained 21 years of age.

10 Part C of the amendment does the following.

11 1. It defines "cannabis pre-roll" for the purposes of the cannabis excise tax using the  
12 same definition of "cannabis pre-roll" in the adult use cannabis program.

13 2. It establishes an excise tax for adult use cannabis pre-rolls as the amount per pound  
14 or fraction thereof of adult use cannabis flower or adult use cannabis trim used in a cannabis  
15 pre-roll.

16 Part D of the amendment does the following.

17 1. It directs the office to provide, beginning January 1, 2027, monthly reports to the  
18 joint standing committee of the Legislature having jurisdiction over cannabis matters on  
19 the performance of the entity that holds the contract with the State for the implementation  
20 and administration of the statewide adult use cannabis inventory tracking system.

21 2. It directs the office to begin, by August 1, 2026, a competitive bidding process for a  
22 statewide inventory tracking system for the medical use of cannabis program.

23 3. It directs the office and the Office of Information Technology within the Department  
24 of Administrative and Financial Services to develop an estimate for a statewide inventory  
25 tracking system for both the medical use of cannabis program and the adult use cannabis  
26 program that is developed, administered and maintained by the State and report back to the  
27 joint standing committee of the Legislature having jurisdiction over cannabis matters by  
28 March 1, 2027 on the cost to develop and implement such a system, the cost to administer  
29 and maintain such a system, the functionality of such a system and a projected timeline for  
30 implementation.

31 Part E of the amendment establishes an effective date of January 1, 2027 for Parts A,  
32 B and C of the amendment.

33 **FISCAL NOTE REQUIRED**

34 **(See attached)**